# US 2022/0031730 A1 · Enhanced oligonucleotides for modulating fubp1 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031730 A1
- Document ID: US20220031730A1
- Status: Published application
- Kind: A1
- Application number: 17/359,196
- Filed: 2021-06-25
- Published: 2022-02-03
- Earliest claimed: 2020-06-26
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Sabine SEWING; Søren OTTOSEN; Jacob RAVN; Lykke PEDERSEN; Souphalone LUANGSAY; Erich KOLLER; Johanna Marie WALTHER; Helene Maria GYLLING; Natascha HRUSCHKA; Susanne MOHR; Valentina D'ARIENZO
- Web page: https://patentgrep.com/patent/US20220031730A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/33: Alteration of splicing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.

## Claims

### Claim 1

An antisense oligonucleotide selected from the group of antisense oligonucleotides consisting of
(SEQ ID NO: 7)
CTtAtgctttttatGgTT,
(SEQ ID NO: 18)
AcCAAttttcatttCtAC,
(SEQ ID NO: 6)
CTTatGctttttatgGT,
(SEQ ID NO: 6)
CTTaTgctttttatgGT,
(SEQ ID NO: 7)
CTtATgctttttatgGTT,
(SEQ ID NO: 7)
CTtAtgctttttatgGTT,
(SEQ ID NO: 7)
CTtAtgctttttatGGTT,
(SEQ ID NO: 8)
GcttTttatggtTtCAC, and
(SEQ ID NO: 9)
TATgcTtntatggtTTC,
wherein capital letters are beta-D-oxy LNA nucleosides, lowercase letters are DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.

### Claim 2 (depends on 1)

A conjugate comprising the antisense oligonucleotide of claim 1, and at least one conjugate moiety covalently attached to said antisense oligonucleotide.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein the at least one conjugate moiety is capable of binding to an asialoglycoprotein receptor.

### Claim 4 (depends on 2)

The conjugate of claim 2, wherein the conjugate moiety is selected from one of the trivalent GalNAc moieties in FIG. 9 as follows:

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein the conjugate moiety is the trivalent GalNAc moiety in FIG. 9D1, or 9D2 or a mixture thereof as follows:

### Claim 6 (depends on 1)

The conjugate of claim 1, comprising a linker positioned between the antisense oligonucleotide and the conjugate moiety.

### Claim 7 (depends on 6)

The conjugate of claim 6, wherein the linker comprises or consists of 2 to 5 consecutive phosphodiester linked nucleosides.

### Claim 8

A conjugate selected from the group of conjugates shown in FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8 and FIG. 8.1 as follows:

### Claim 9 (depends on 1)

A pharmaceutically acceptable salt of the oligonucleotide of claim 1.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the antisense oligonucleotide of claim 1, and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

### Claim 11 (depends on 1)

An in vivo or in vitro method for modulating FUBP1 expression in a target cell which is expressing FUBP1, said method comprising administering the antisense oligonucleotide of claim 1 in an effective amount to said cell.

### Claim 12 (depends on 1)

A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of the antisense oligonucleotide of claim 1 to a subject suffering from or susceptible to the disease, wherein the disease is hepatitis B virus (HBV) infection and/or cancer.

### Claim 13 (depends on 1)

The antisense oligonucleotide of claim 1, for use in medicine.

### Claim 14 (depends on 1)

The antisense oligonucleotide of claim 1, for use in the treatment or prevention of hepatitis B virus (HBV) infection and/or cancer.

### Claim 15 (depends on 1)

Use of the antisense oligonucleotide of claim 1, for the preparation of a medicament for treatment or prevention of a hepatitis B virus (HBV) infection and/or cancer.

### Claim 16 (depends on 12)

The method of claim 12, wherein the disease is hepatitis B virus (HBV) infection, such as chronic HBV infection.

### Claim 17 (depends on 12)

The method of claim 12, wherein the disease is cancer, such as hepatocellular carcinoma.
